Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans
Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data Credit: Team […]
Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data
Credit: Team BIPID, Université Paris Cité (CC-BY 4.0, https://creativecommons.org/licenses/by/4.0/)
Despite use of tecovirimat since the beginning of the 2022 mpox outbreak, few data have been published on its antiviral effect in humans; this study predicts the impact of early tecovirimat administration on the time to viral clearance in patients with mpox infection, using an integrative modeling approach combining pre-clinical and clinical data
#####
In your coverage, please use this URL to provide access to the freely available paper in PLOS Biology: http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.3002249
Article Title: Early administration of tecovirimat shortens the time to mpox clearance in a model of human infection
Author Countries: France, Spain, United Kingdom, United States, Papua New Ginea
Funding: BTN received funding from IAME UMR 137, Université Paris Cité, INSERM, F-75018, Paris, France (https://www.iame-research.center/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Journal
PLoS Biology
DOI
10.1371/journal.pbio.3002249
Method of Research
Computational simulation/modeling
Subject of Research
Not applicable
COI Statement
Competing interests: I have read the journal’s policy and the authors of this manuscript have the following competing interests: DWG, DEH, and ATR work for SIGA Technologies Inc. Other authors declare no conflicts of interests.
What's Your Reaction?
